Özdem Kavraz Tomar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Özdem Kavraz Tomar has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Tülin Akagün
Division of Nephrology, Department of Internal Medicine, Giresun University Faculty of Medicine, Giresun, Türkiye
3 shared publications - Murat Duranay
Department of Nephrology, Ankara Training and Research Hospital, Health Sciences University, 06230 Ankara, Türkiye
2 shared publications - Abdulkadir Unsal
Şişli Hamidiye Etfal Education and Research Hospital, Istanbul, Türkiye
1 shared publication - Ahmet Cumhur Dülger
Department of Gastroenterology, Giresun University Faculty of Medicine, Giresun, Turkey
1 shared publication - Ahmet Kiykim
Division of Nephrology, Department of Internal Medicine, School of Medicine, Mersin University, 33079, Mersin, Turkey
1 shared publication - Ali Gurel
Firat Universitesi
1 shared publication
Latest Publications
- 27 October 2026
- Published by Elsevier in Advances in Medical Sciences
- Vol. 71 (2) , 422-427
Diagnostic value of the systemic inflammation response index (SIRI) in predicting a low TAPSE/sPAP ratio in hemodialysis patients
- 27 October 2026
- Published by Elsevier in Advances in Medical Sciences
- Vol. 71 (2) , 422-427
Diagnostic value of the systemic inflammation response index (SIRI) in predicting a low TAPSE/sPAP ratio in hemodialysis patients
- Open Access
Morning Hypertension as a Factor Independently Associated with Renal Dysfunction in Hypertensive Patients with Chronic Kidney Disease
Background and Objectives: Hypertension is highly prevalent among individuals with chronic kidney disease (CKD) and contributes substantially to both cardiovascular morbidity and progressive renal dysfunction. Ambulatory blood pressure monitoring (ABPM) provides superior diagnostic accuracy compared with office measurements and is recommended for evaluating blood pressure patterns and hypertension-mediated organ damage in CKD. Morning blood pressure, in particular, has gained increasing attention due to its association with adverse cardiovascular and renal outcomes. However, evidence regarding the independent impact of morning hypertension in CKD remains limited. This study aimed to determine the prevalence of morning and nocturnal hypertension phenotypes in hypertensive CKD patients and to evaluate their associations with renal and cardiac target organ damage. Materials and Methods: A total of 132 patients with CKD stages 1–5 underwent 24-h ABPM, transthoracic echocardiography, and comprehensive biochemical evaluation. Morning and nocturnal hypertension were defined according to ESC 2024 guidelines. Demographic, clinical, echocardiographic, and renal parameters were compared between groups. Correlation analyses were performed to explore associations between blood pressure phenotypes and markers of target organ damage. Multivariable regression models were used to assess independent predictors of renal and cardiac structural alterations. Results: Morning hypertension was present in 42.4% of patients, whereas nocturnal hypertension was detected in 78%. Patients with morning hypertension exhibited significantly lower eGFR and higher UACR levels (both p < 0.001). Morning hypertension showed positive correlations with creatinine, urea, PTH, ESR, and UACR, and negative correlations with eGFR, albumin, calcium, hemoglobin, and TAPSE. In multivariable regression, morning hypertension was independently associated with lower eGFR (β = −0.26; p = 0.002). Nocturnal hypertension was positively associated with IVSd (β = 0.19; p = 0.024) and UACR, supporting its role in cardiac remodeling and renal injury. Conclusions: Morning hypertension may represent a clinically relevant blood pressure phenotype in CKD and may be associated with markers of renal dysfunction; however, longitudinal studies are needed to determine its prognostic significance. The strong associations of nocturnal hypertension with IVSd and albuminuria further highlight the importance of evaluating 24-h blood pressure patterns. Incorporating ABPM into routine clinical practice may enhance risk stratification and guide individualized treatment strategies in CKD.
Open AccessMorning Hypertension as a Factor Independently Associated with Renal Dysfunction in Hypertensive Patients with Chronic Kidney Disease
Background and Objectives: Hypertension is highly prevalent among individuals with chronic kidney disease (CKD) and contributes substantially to both cardiovascular morbidity and progressive renal dysfunction. Ambulatory blood pressure monitoring (ABPM) provides superior diagnostic accuracy compared with office measurements and is recommended for evaluating blood pressure patterns and hypertension-mediated organ damage in CKD. Morning blood pressure, in particular, has gained increasing attention due to its association with adverse cardiovascular and renal outcomes. However, evidence regarding the independent impact of morning hypertension in CKD remains limited. This study aimed to determine the prevalence of morning and nocturnal hypertension phenotypes in hypertensive CKD patients and to evaluate their associations with renal and cardiac target organ damage. Materials and Methods: A total of 132 patients with CKD stages 1–5 underwent 24-h ABPM, transthoracic echocardiography, and comprehensive biochemical evaluation. Morning and nocturnal hypertension were defined according to ESC 2024 guidelines. Demographic, clinical, echocardiographic, and renal parameters were compared between groups. Correlation analyses were performed to explore associations between blood pressure phenotypes and markers of target organ damage. Multivariable regression models were used to assess independent predictors of renal and cardiac structural alterations. Results: Morning hypertension was present in 42.4% of patients, whereas nocturnal hypertension was detected in 78%. Patients with morning hypertension exhibited significantly lower eGFR and higher UACR levels (both p < 0.001). Morning hypertension showed positive correlations with creatinine, urea, PTH, ESR, and UACR, and negative correlations with eGFR, albumin, calcium, hemoglobin, and TAPSE. In multivariable regression, morning hypertension was independently associated with lower eGFR (β = −0.26; p = 0.002). Nocturnal hypertension was positively associated with IVSd (β = 0.19; p = 0.024) and UACR, supporting its role in cardiac remodeling and renal injury. Conclusions: Morning hypertension may represent a clinically relevant blood pressure phenotype in CKD and may be associated with markers of renal dysfunction; however, longitudinal studies are needed to determine its prognostic significance. The strong associations of nocturnal hypertension with IVSd and albuminuria further highlight the importance of evaluating 24-h blood pressure patterns. Incorporating ABPM into routine clinical practice may enhance risk stratification and guide individualized treatment strategies in CKD.
- Open Access
- 23 January 2026
- Published by Giresun Training and Research Hospital in Cerasus Journal of Medicine
- Vol. 3 (1) , 18-27
Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study
Objective: This study aimed to compare haematological, biochemical, and serological parameters in haemodialysis (HD) patients with Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) in order to identify distinctive laboratory patterns with potential clinical relevance. Methods: This cross-sectional study included 77 patients undergoing HD at a tertiary centre: 45 with AKI and 32 with CKD. Demographic characteristics and a broad panel of laboratory parameters encompassing haematological indices, inflammatory markers, liver and cholestatic enzymes, electrolyte and mineral metabolism, iron parameters, and serological markers were analysed. Group comparisons were performed using appropriate statistical tests. Receiver Operating Characteristic (ROC) analyses were conducted for Helicobacter pylori (HP) IgA and IgG. Results: Patients with AKI were significantly older than those with CKD (p=0.001), while sex distribution was similar. Compared with CKD patients, the AKI group demonstrated a laboratory profile characterised by higher inflammatory and tissue injury markers, including white blood cell count, neutrophils, C-reactive protein, lactate dehydrogenase, and D-dimer (all p<0.05). In contrast, CKD patients exhibited higher levels of creatinine, parathyroid hormone, ferritin, iron indices, and alkaline phosphatase, consistent with chronic kidney disease–related metabolic alterations (all p<0.05). No significant differences were observed in HP IgA or IgG levels, and ROC analyses showed no discriminative value for distinguishing AKI from CKD. Conclusion: HD patients with AKI and CKD exhibit distinct multisystem laboratory patterns reflecting acute inflammatory activity versus chronic metabolic adaptation. Recognising these differences may improve contextual interpretation of laboratory findings and support more individualised clinical decision-making in the HD setting.
- 23 January 2026
- Published by Giresun Training and Research Hospital in Cerasus Journal of Medicine
- Vol. 3 (1) , 18-27
Open AccessHaematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study
Objective: This study aimed to compare haematological, biochemical, and serological parameters in haemodialysis (HD) patients with Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) in order to identify distinctive laboratory patterns with potential clinical relevance. Methods: This cross-sectional study included 77 patients undergoing HD at a tertiary centre: 45 with AKI and 32 with CKD. Demographic characteristics and a broad panel of laboratory parameters encompassing haematological indices, inflammatory markers, liver and cholestatic enzymes, electrolyte and mineral metabolism, iron parameters, and serological markers were analysed. Group comparisons were performed using appropriate statistical tests. Receiver Operating Characteristic (ROC) analyses were conducted for Helicobacter pylori (HP) IgA and IgG. Results: Patients with AKI were significantly older than those with CKD (p=0.001), while sex distribution was similar. Compared with CKD patients, the AKI group demonstrated a laboratory profile characterised by higher inflammatory and tissue injury markers, including white blood cell count, neutrophils, C-reactive protein, lactate dehydrogenase, and D-dimer (all p<0.05). In contrast, CKD patients exhibited higher levels of creatinine, parathyroid hormone, ferritin, iron indices, and alkaline phosphatase, consistent with chronic kidney disease–related metabolic alterations (all p<0.05). No significant differences were observed in HP IgA or IgG levels, and ROC analyses showed no discriminative value for distinguishing AKI from CKD. Conclusion: HD patients with AKI and CKD exhibit distinct multisystem laboratory patterns reflecting acute inflammatory activity versus chronic metabolic adaptation. Recognising these differences may improve contextual interpretation of laboratory findings and support more individualised clinical decision-making in the HD setting.
- 6 January 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 3223-3230
Validity and reliability of the Turkish version of the uremic pruritus in dialysis patients (UP-Dial) scale
Uremic pruritus significantly impairs the quality of life in hemodialysis (HD) patients, a specific assessment tool for this population is lacking. The primary purpose of this study was to translate the Uremic Pruritus in Dialysis Patients (UP-Dial) scale into Turkish and evaluate its validity and reliability. In this methodological study, 181 HD patients with pruritus were included. The reliability of the Turkish UP-Dial scale was tested using Cronbach's alpha values for internal consistency. Construct validity was examined via exploratory factor analyses (EFA) and confirmatory factor analyses (CFA). Convergent validity was assessed by correlating the UP-Dial with the Numerical Rating Scale (NRS), 5-D Itch Scale, and Dermatology Life Quality Index (DLQI). Following item analysis, item 7 (xerosis) was excluded due to low item-total correlation. The 13-item Turkish UP-Dial demonstrated excellent internal consistency (Cronbach's α = 0.90) and test-retest reliability (ICC = 0.98; 95% CI = 0.97-0.99). EFA revealed a four-factor structure explaining 78.5% of the total variance, and CFA demonstrated good model fit (χ2/df = 1.97, RMSEA = 0.07, CFI = 0.97, GFI = 0.91). Strong correlations were found between UP-Dial total scores and NRS (r = 0.82), 5-D Itch Scale (r = 0.87), and DLQI (r = 0.80) (all p < 0.001). The 13-item Turkish UP-Dial is a valid and reliable tool for multidimensional assessment of uremic pruritus in HD patients. It may provide standardized follow-up and evaluation of responses to both pharmacologic and non-pharmacologic treatments for uremic pruritus.
- 6 January 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (8) , 3223-3230
Validity and reliability of the Turkish version of the uremic pruritus in dialysis patients (UP-Dial) scale
Uremic pruritus significantly impairs the quality of life in hemodialysis (HD) patients, a specific assessment tool for this population is lacking. The primary purpose of this study was to translate the Uremic Pruritus in Dialysis Patients (UP-Dial) scale into Turkish and evaluate its validity and reliability. In this methodological study, 181 HD patients with pruritus were included. The reliability of the Turkish UP-Dial scale was tested using Cronbach's alpha values for internal consistency. Construct validity was examined via exploratory factor analyses (EFA) and confirmatory factor analyses (CFA). Convergent validity was assessed by correlating the UP-Dial with the Numerical Rating Scale (NRS), 5-D Itch Scale, and Dermatology Life Quality Index (DLQI). Following item analysis, item 7 (xerosis) was excluded due to low item-total correlation. The 13-item Turkish UP-Dial demonstrated excellent internal consistency (Cronbach's α = 0.90) and test-retest reliability (ICC = 0.98; 95% CI = 0.97-0.99). EFA revealed a four-factor structure explaining 78.5% of the total variance, and CFA demonstrated good model fit (χ2/df = 1.97, RMSEA = 0.07, CFI = 0.97, GFI = 0.91). Strong correlations were found between UP-Dial total scores and NRS (r = 0.82), 5-D Itch Scale (r = 0.87), and DLQI (r = 0.80) (all p < 0.001). The 13-item Turkish UP-Dial is a valid and reliable tool for multidimensional assessment of uremic pruritus in HD patients. It may provide standardized follow-up and evaluation of responses to both pharmacologic and non-pharmacologic treatments for uremic pruritus.
- Open Access
- 8 June 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Pre-earthquake kidney function is a predictor of outcomes in earthquake-related crush syndrome
The devastating earthquakes in Kahramanmaraş, Türkiye, in February 2024, caused extensive trauma and loss of lives, causing unique challenges in the management of earthquake-related crush syndrome. The current study investigates the prognostic value of pre-earthquake kidney function for mortality prediction in patients diagnosed with crush syndrome. A multi-center retrospective analysis was performed using data from 469 patients treated at 46 nephrology clinics. Pre-earthquake Kidney function, defined by serum creatinine and estimated glomerular filtration rate (eGFR) levels, was obtained from pre-earthquake health records. Clinical findings, laboratory parameters, complications, and survival probabilities were analyzed. Multivariate Cox regression was used to identify independent predictors of in-hospital mortality. The mean age of participants was 42.56 ± 16.92 years (Non-survivors: 50.46 ± 20.03 years, Survivors: 42.34 ± 16.80 years (p = 0.172)). The in-hospital mortality rate was 2.8%. Non-survivors exhibited significantly higher pre-earthquake creatinine levels than survivors (1.04 ± 0.61 mg/dL vs. 0.77 ± 0.33 mg/dL, p = 0.03), with lower eGFR (85.2 ± 34.7 mL/min/1.73 m² vs. 115.8 ± 39.4 mL/min/1.73 m², p = 0.008). Compared with survivors, non-survivors had higher incidences of AKI (92.3% vs. 61.6%, p = 0.037) and more severe metabolic disturbances, including hyperkalemia (5.41 ± 1.72 mmol/L vs. 5.13 ± 0.98 mmol/L, p = 0.008). Regression analysis revealed that pre-earthquake creatinine (HR: 9.121, 95% CI: 2.686–30.970, p < 0.001) and potassium levels at admission (HR: 3.338, 95% CI: 1.540–7.232, p = 0.002) were independent predictors of mortality. Pre-earthquake kidney function significantly predicts mortality in crush syndrome patients, highlighting the importance of baseline kidney assessment in disaster preparedness.
- 8 June 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-9
Open AccessPre-earthquake kidney function is a predictor of outcomes in earthquake-related crush syndrome
The devastating earthquakes in Kahramanmaraş, Türkiye, in February 2024, caused extensive trauma and loss of lives, causing unique challenges in the management of earthquake-related crush syndrome. The current study investigates the prognostic value of pre-earthquake kidney function for mortality prediction in patients diagnosed with crush syndrome. A multi-center retrospective analysis was performed using data from 469 patients treated at 46 nephrology clinics. Pre-earthquake Kidney function, defined by serum creatinine and estimated glomerular filtration rate (eGFR) levels, was obtained from pre-earthquake health records. Clinical findings, laboratory parameters, complications, and survival probabilities were analyzed. Multivariate Cox regression was used to identify independent predictors of in-hospital mortality. The mean age of participants was 42.56 ± 16.92 years (Non-survivors: 50.46 ± 20.03 years, Survivors: 42.34 ± 16.80 years (p = 0.172)). The in-hospital mortality rate was 2.8%. Non-survivors exhibited significantly higher pre-earthquake creatinine levels than survivors (1.04 ± 0.61 mg/dL vs. 0.77 ± 0.33 mg/dL, p = 0.03), with lower eGFR (85.2 ± 34.7 mL/min/1.73 m² vs. 115.8 ± 39.4 mL/min/1.73 m², p = 0.008). Compared with survivors, non-survivors had higher incidences of AKI (92.3% vs. 61.6%, p = 0.037) and more severe metabolic disturbances, including hyperkalemia (5.41 ± 1.72 mmol/L vs. 5.13 ± 0.98 mmol/L, p = 0.008). Regression analysis revealed that pre-earthquake creatinine (HR: 9.121, 95% CI: 2.686–30.970, p < 0.001) and potassium levels at admission (HR: 3.338, 95% CI: 1.540–7.232, p = 0.002) were independent predictors of mortality. Pre-earthquake kidney function significantly predicts mortality in crush syndrome patients, highlighting the importance of baseline kidney assessment in disaster preparedness.
- 1 October 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (10) , 708-712
Assessment of symptom frequency and severity in hemodialysis patients using the dialysis symptom index (DSI); a single center experience
Aim Hemodialysis (HD) patients may experience many symptoms, such as fatigue, muscle cramps, headaches, and decreased sexual desire, with the severity of these symptoms varying individually. This study aimed to evaluate the frequency and severity of symptoms in HD patients using the dialysis symptom index (DSI), which provides an assessment of non-fatal physical and emotional symptoms that negatively affect quality of life. Methods Patients aged 18 years and over who received hemodialysis treatment for at least three months at the hemodialysis unit of Giresun Training and Research Hospital, who agreed to participate in the study and signed the consent form, and who were conscious and had no communication problems were included in the study. Data were collected using a face-to-face interview method and the Dialysis Symptom Index. Results Of the 97 patients included in the study, 53 were male, 44 were female, and the mean age was 58 years. There was a statistically significant difference in DSI scores between male and female patients. Female patients complained of physical and emotional symptoms more often than male patients. The most common and most severe symptom described by the patients, according to DSI, was feeling tired/decreased energy (90.7%) and decreased interest in sexual intercourse (92.8%). More than half of the patients in the study complained of muscle cramps (62.9%), numbness and tingling in the feet (54.6%), feeling sad (73.2%), and dry skin (72.2%). Conclusion Symptoms of patients receiving HD treatment should be monitored at regular intervals, and the awareness of health professionals providing care to this patient group should be increased.
- 1 October 2024
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 15 (10) , 708-712
Assessment of symptom frequency and severity in hemodialysis patients using the dialysis symptom index (DSI); a single center experience
Aim Hemodialysis (HD) patients may experience many symptoms, such as fatigue, muscle cramps, headaches, and decreased sexual desire, with the severity of these symptoms varying individually. This study aimed to evaluate the frequency and severity of symptoms in HD patients using the dialysis symptom index (DSI), which provides an assessment of non-fatal physical and emotional symptoms that negatively affect quality of life. Methods Patients aged 18 years and over who received hemodialysis treatment for at least three months at the hemodialysis unit of Giresun Training and Research Hospital, who agreed to participate in the study and signed the consent form, and who were conscious and had no communication problems were included in the study. Data were collected using a face-to-face interview method and the Dialysis Symptom Index. Results Of the 97 patients included in the study, 53 were male, 44 were female, and the mean age was 58 years. There was a statistically significant difference in DSI scores between male and female patients. Female patients complained of physical and emotional symptoms more often than male patients. The most common and most severe symptom described by the patients, according to DSI, was feeling tired/decreased energy (90.7%) and decreased interest in sexual intercourse (92.8%). More than half of the patients in the study complained of muscle cramps (62.9%), numbness and tingling in the feet (54.6%), feeling sad (73.2%), and dry skin (72.2%). Conclusion Symptoms of patients receiving HD treatment should be monitored at regular intervals, and the awareness of health professionals providing care to this patient group should be increased.
- 19 August 2024
- Published by Giresun Training and Research Hospital in Cerasus Journal of Medicine
Home Hemodialysis
Chronic kidney disease (CKD) is a public health problem with increasing prevalence worldwide and is associated with significant morbidity and mortality . According to 2022 data, there are a total of 13725 patients receiving renal replacement therapy (RRT) for end-stage renal disease (ESRD) in Turkey. Hemodialysis (HD) accounts for a large proportion of patients receiving RRT with 10287 patients . Although kidney transplantation is the best treatment option for patients with ESRD, the majority of patients do not have access to this treatment for various reasons. Most patients are treated with HD and peritoneal dialysis (PD), which are traditional methods of RRT. HD has two modalities: conventional HD and home hemodialysis (HHD).
- 19 August 2024
- Published by Giresun Training and Research Hospital in Cerasus Journal of Medicine
Home Hemodialysis
Chronic kidney disease (CKD) is a public health problem with increasing prevalence worldwide and is associated with significant morbidity and mortality . According to 2022 data, there are a total of 13725 patients receiving renal replacement therapy (RRT) for end-stage renal disease (ESRD) in Turkey. Hemodialysis (HD) accounts for a large proportion of patients receiving RRT with 10287 patients . Although kidney transplantation is the best treatment option for patients with ESRD, the majority of patients do not have access to this treatment for various reasons. Most patients are treated with HD and peritoneal dialysis (PD), which are traditional methods of RRT. HD has two modalities: conventional HD and home hemodialysis (HHD).
- Open Access
- 30 January 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 274-282
Platelet activating factor acetylhydrolase is associated with cardiac valvular calcification in dialysis patients
Objectives: The cardiovascular mortality risk is greatly increased in patients with chronic kidney disease (CKD), especially in dialysis patients, due to atherosclerosis. Platelet activating factor acetylhydrolase (PAF-AH) is an enzyme that hydrolyzes platelet activating factor (PAF). Valvular calcifications and PAF-AH are associated with atherosclerosis. However, little is known about the status of PAF-AH activity and valvular calcification in dialysis patients. Therefore, the aim of this study was to investigate the status of these parameters in CKD patients. Methods: This study included 92 chronic renal failure (CRF) (dialysis group), and 86 CKD patients (non-dialysis group). Echocardiography was performed to assess valvular calcification. Results: There was no significant difference between the dialysis and CKD groups in terms of PAF-AH activities. However, when comparisons were stratified according to the presence of valve calcification, higher PAF-AH activity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were evident in patients with calcification compared to those without. Additionally, the CRF group also exhibited elevated PAF-AH and NT-proBNP levels. While elevated NT-proBNP persisted in the CKD group, in contrast, changes in PAF-AH were not significant. Conclusions: The results of this study suggest that high PAF-AH and NT-proBNP levels are associated with valvular calcification in dialysis patients. Both biomarkers may be used as a risk factor for calcification. Furthermore, inhibition of PAF-AH activity may be a treatment target to reduce calcification.
- 30 January 2024
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 49 (2) , 274-282
Open AccessPlatelet activating factor acetylhydrolase is associated with cardiac valvular calcification in dialysis patients
Objectives: The cardiovascular mortality risk is greatly increased in patients with chronic kidney disease (CKD), especially in dialysis patients, due to atherosclerosis. Platelet activating factor acetylhydrolase (PAF-AH) is an enzyme that hydrolyzes platelet activating factor (PAF). Valvular calcifications and PAF-AH are associated with atherosclerosis. However, little is known about the status of PAF-AH activity and valvular calcification in dialysis patients. Therefore, the aim of this study was to investigate the status of these parameters in CKD patients. Methods: This study included 92 chronic renal failure (CRF) (dialysis group), and 86 CKD patients (non-dialysis group). Echocardiography was performed to assess valvular calcification. Results: There was no significant difference between the dialysis and CKD groups in terms of PAF-AH activities. However, when comparisons were stratified according to the presence of valve calcification, higher PAF-AH activity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were evident in patients with calcification compared to those without. Additionally, the CRF group also exhibited elevated PAF-AH and NT-proBNP levels. While elevated NT-proBNP persisted in the CKD group, in contrast, changes in PAF-AH were not significant. Conclusions: The results of this study suggest that high PAF-AH and NT-proBNP levels are associated with valvular calcification in dialysis patients. Both biomarkers may be used as a risk factor for calcification. Furthermore, inhibition of PAF-AH activity may be a treatment target to reduce calcification.
- 1 February 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (6) , 1629-1634
The prevalence of Fabry disease in a Turkish population with chronic kidney patients
Background and objectives Fabry disease (FD) is an X-linked lysosomal storage disease with various clinical symptoms due to a deficiency of an enzyme called alpha-galactosidase A. The likelihood of nephropathy increases with age and the severity of the mutation in Fabry patients. Fabry disease is difficult to diagnose. The exact incidence and prevalence of Fabry disease are unknown due to its atypical or oligosymptomatic forms. Design, setting, participants, and measurements GLA gene mutations were examined in patients over the age of 18 who were followed up on with a diagnosis of chronic kidney disease and who had or did not receive renal replacement therapy from October 2017 to December 2019. Results A total of 18 sites in 8 locations around Turkey volunteered to participate in the study, including people aged 18 and older with stages 1–5 of chronic kidney disease (CKD) or getting renal replacement therapy. 1904 patients were screened in total. In 13 cases, a D313Y pseudo mutation in the GLA gene was discovered. GLA gene mutations were found and pathologically assessed in four of the tested cases. Conclusions The range of clinical symptoms of Fabry disease, as well as the frequent delays in diagnosis, result in treatment being too late. We believe that screening chronic renal patients at high risk for Fabry disease is warranted.
- 1 February 2023
- Published by Springer Nature in International Urology and Nephrology
- Vol. 55 (6) , 1629-1634
The prevalence of Fabry disease in a Turkish population with chronic kidney patients
Background and objectives Fabry disease (FD) is an X-linked lysosomal storage disease with various clinical symptoms due to a deficiency of an enzyme called alpha-galactosidase A. The likelihood of nephropathy increases with age and the severity of the mutation in Fabry patients. Fabry disease is difficult to diagnose. The exact incidence and prevalence of Fabry disease are unknown due to its atypical or oligosymptomatic forms. Design, setting, participants, and measurements GLA gene mutations were examined in patients over the age of 18 who were followed up on with a diagnosis of chronic kidney disease and who had or did not receive renal replacement therapy from October 2017 to December 2019. Results A total of 18 sites in 8 locations around Turkey volunteered to participate in the study, including people aged 18 and older with stages 1–5 of chronic kidney disease (CKD) or getting renal replacement therapy. 1904 patients were screened in total. In 13 cases, a D313Y pseudo mutation in the GLA gene was discovered. GLA gene mutations were found and pathologically assessed in four of the tested cases. Conclusions The range of clinical symptoms of Fabry disease, as well as the frequent delays in diagnosis, result in treatment being too late. We believe that screening chronic renal patients at high risk for Fabry disease is warranted.